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Gastrin has been postulated to stimulate proliferation in colorectal neoplasms. Although 
gastrin mRNA has been demonstrated to be present in colon cancer cell lines, the intact peptide 
had not been recovered from human colorectal neoplasms. 
We demonstrate that gastrin and its precursors are present in both colorectal neoplasia 
and adjacent normal-appearing colonic mucosa. In colonic tissue, the glycine-extended 
precursor form of the peptide is over lo-fold more abundant than the amidated gastrin, and 
progastrin is more than 700-fold more abundant. In contrast, amidated gastrin in the human 
antrum is the predominant form of gastrin by a factor of 10. Furthermore, the ratio of gastrin 
precursors to gastrin is significantly increased in neoplastic colonic mucosa when compared with 
normal colonic tissue. These data suggest that the processing of gastrin is unique in the human 
colon and that further differences in processing occur in neoplastic colonic tissue. Q 1992 Academic 
mes.5, 1°C. 
Colorectal carcinoma is the second most common cancer in the US, accounting for 
156,000 new patients and 58,000 deaths per year.(l) Colorectal carcinoma has an overall 
survival rate of 50 to 60% at 5 years with current treatment modalities(2) A recurrent theme 
found in the study of proliferation of cancers, including breast, thyroid, and prostate carcinomas, 
is the role of peptides in the promotion of tumor growth.0) Hormonal manipulation of these 
tumors has led to significant advances in diagnosis, treatment, and patient outcome. Colon 
cancer may well be added to this list, as gastrin has been postulated to play a role in the 
promotion of the growth of colorectal carcinoma in viva via an autocrine mechanism.(4) In fact, 
serum gastrin levels have been shown to be elevated in some patients with colonic adenomas and 
carcinomas.(5,6) The return of gastrin levels to the normal range has been reported following 
resection of these neoplasms.(7,8) Despite this observation, others have examined neoplastic 
tissue resected at surgery and have been unable to detect gastrin(9) 
Gastrin, a peptide found predominantly in gastric antrum, has multiple effects on the 
gastrointestinal (GI) tract. These effects include stimulation of parietal cell growth, acid 
secretion, and trophism for the GI tract during various stages of development.(lO) Gastrin is 
synthesized as a pre-prohormone which requires post-translational modification for its biological 
activation. The pre-prohormone undergoes several processing steps to yield a carboxyl-terminal 
glycine-extended precursor, as outlined in Figure l.( 11) The glycine-extended intermediate then 
undergoes carboxyamidation to yield the amidated, biologically active, hormone. Amidated 
gastrin itself may exist in various molecular forms in tissue and in serum. G-14, G-17, G-34 and 
other forms sharing a common amidated carboxyl-terminus have been identified. All circulating 
forms are roughly equipotent, on a molar basis, for stimulation of gastric acid secretion. 
Gastrin has been demonstrated to stimulate the cellular proliferation of several colonic 
tumor models in a specific manner. Mouse and human colon cancer cell lines and rat colorectal 
cancer models demonstrate increased proliferation in response to exogenous gastrin, to have 
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Fi ure 1. Processing schema for progastrin and antibody specificity for antibodies 1611,5135, 
37. as described in the text. Gastrin refers to all molecular forms of gastrin, including 
sulfated forms, such as G-14, G-17, G-17S, G-34, and G-34s. In viva progasuin undergoes 
proteolytic cleavage by prohormone convertase and carboxypeptidase H to yield glycine- 
extended gastrin (G-gly). In vitro progastrin is cleaved by trypsin and carboxypeptidase B to 
yield G-gly. The arnidating enzyme cleaves the carboxyl-terminal glycine and replaces it with an 
amide group to yield the biologically active form of gasuin. 
gastrin receptors or binding sites, and the proliferative effects of gastrin are reversed when 
gas&in-receptor antagonists ate applied (12,13,14,15,16). 
The source and the role of gastrin in colonic neoplasia is controversial. It has been 
postulated that gas&in has an autocrine role in colorectal neoplasia, although identification of the 
intact peptide or its precursors has not been reported in human tissue. Identification of gastrin 
may be difficult due to multiple factors, including low quantity of processed peptide and assay 
insensitivity. We hypothesize that gastrin processing may be altered in neoplastic tissue. Our 
purpose in undertaking this series of experiments was to identify gastrin and its precursors in 
human neoplastic and non-neoplastic colonic tissue. 
ue Collectioq: 
Matched paired samples of tumor and normal-appearing adjacent colonic mucosa were 
obtained from 15 patients undergoing resection for colorectal carcinoma. Tissue was collected, 
colonic mucosa was bluntly dissected away from submucosa, and quickly frozen and stored at 
-70’ c. 
Tissue samples were weighed and placed while still frozen into boiling double-distilled 
water (10 ml/g). The tissues were boiled for ten minutes, homogenized using a high-speed 
mechanical homogenizer (Polytron, Brinkman, Switzerland), and boiled a second time to insure 
inactivation of proteolytic enzymes. The extracts were then centrifuged at 30,OOOG at 4°C for 30 
minutes. The suuernatant was saved and stored at -70°C until needed. 
Radioimmunoassays specific for gastrin, glycine-extended gastrin (G-gly), and progastrin 
were performed as previously described utilizing antibodies 1611,5135, and 8237, as illustrated 
in Figure 1 (17,18,19). 
For gastrin assay we utilized antibodies 1611 and 5135, generous gifts from Dr. John 
Walsh (Los Angeles, California). Antibody 5135 is specific for the carboxyl-terminus of the 
amidated forms of gastrin, cross-reacts 100% with amidated CCK, and ~1% with glycine- 
extended forms of peptides. For confirmation of gas&in immunoreactivity, we utilized antibody 
1611, which is specific for the carboxyl-terminus of the amidated forms of gastrin and cross- 
reacts ~1% with CCK and glycine-extended forms of gastrin. 
1166 
Vol. 189, No. 2, 1992 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
Glycine-extended gastrin was assayed utilizing antibody 8237 which is specific for 
gastrin and cholecystokinin peptides with carboxyl-terminal glycine extensions but cross-reacts 
~1% with amidated peptides or peptides with extensions beyond the glycine residue. 
Progastrin content was determined using a modified trypsin/carboxypeptidase B reaction 
coupled with the measurement of G-gly immunoreactivity as described by Rehfeld.(20,21) 
Briefly, G-gly immunoreactivity was fiit determined in an aliquot of the sample. 200 l.rl of the 
sample were added to 300 1.11 of phosphate buffer at pH 7.5 and then digested in 500 ~1 of a 
trypsin (Sigma, St. Louis, Missouri) solution (lOO&@nl) for 30 minutes at room temperature. 
The sample was boiled for 10 minutes to inactivate the trypsin, and centrifuged for 5 minutes at 
1500 RPM at 4’ C. 250 ~1 of the supematant were placed in 650 l.rl of the phosphate buffer and 
100 jr1 of carboxypeptidase B (Sigma, St. Louis, Missouri) (750 units/ml) were added for a 30 
minute incubation. The reaction was stopped by boiling for 10 minutes, and the samples were 
frozen at -70°C until assayed with antibody 8237 for G-gly immunoreactivity. . . * . sucalA alvsls, 
Det&nination of means, standard errors, and t-test were performed utilizing Statworks 
software on a Macintosh SE. 
Uentification of Gastrin and Gastrm murso s 
We first characterized gastrin content kd its processing intermediates in fifteen matched 
pairs of colonic tissues obtained from patients who had undergone surgical resection for 
colorectal neoplasia. Samples were obtained from the tumors and from normal-appearing 
colonic mucosa at least 5 centimeters from the tumor. Individual samples ranged in size from 400 
to 2000 mg. Six cancers were right-sided, 6 were left-sided and 3 were rectal adenocarcinomas. 
No tumors were Dukes A, 1 was Dukes Bl (extending into the muscularis propria), 5 were 
Dukes B2 (extending through the serosa), 2 were Dukes B3 (involving contiguous structures), 4 
were Dukes Cl (5 4 regional lymph nodes involved), 2 were Dukes C2 (> 4 regional lymph 
nodes involved) and 1 was Dukes D (distant metastasis). 
As depicted in Table 1, significantly higher concentrations of amidated gastrin were 
found in the normal appearing mucosa (212k41.8 fmol/g) when compared to the neoplastic 
mucosa (151ti3.5 fmol/g) (p=O.O35). Antibody 1611, specific for am&ted gastrin, confirmed 
the presence of amidated gastrin. Neoplastic mucosa contained significantly greater amounts of 
glycine-extended gastin (2,710&251 fmol/g) when compared to the normal appearing mucosa 
(1,82@219 fmol/g) (pcO.001). Differences between progastrin content in the normal colonic 
tissue (103,000&28,900 fmol/g) and in the neoplastic tissue (124,0~5,000 fmol/g) did not 
reach statistical significance (p=O. 12). 
Of particular interest is the relative ratio of glycine-extended gastrin to amidated gastrin, 
shown in Table 2. The ratio is significantly greater in the neoplastic tissue (27.1k7.78) than in 
the normal-appearing mucosa (11.7f1.84) (p=O.O07). The progastrin to gastrin ratio approached 
significance @==0.067) when the normal mucosa was compared to the neoplastic mucosa. The 
ratios of progastrin to G-gly were not significantly different @=0.17) when the normal appearing 
mucosa was compared to the neoplastic tissue. 
No relationship between either gastrin or precursor content and location of tumor, Dukes 
stage, or size of primary tumor were detected during analysis. 
rlQlI.dEplpn carcinoma D-value 
Gasuin 213f41.8 151f23.5 p=o.o35 
G-gly 1,820&219 2,7OOk25 1 p<O.ool 
Progastrin 103,~8,900 124,OOO~Q5,000 p=o.12 
Note: Results expressed as mean f S.E.M., fmol/g wet tissue, n=15 matched pairs. 
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ll!xmalh gxcinoma D-value 
G-gly/gastrin 11.7f1.84 27.1k7.78 
ProgastrWgastrin 706Sll 1,390&570 p=O.O67 
ProgastrWG-gly 73.31k28.4 48.4k9.21 p=o.17 
Note: Results expressed as mean + S.E.M., fmol/g wet tissue, n=15 matched pairs. 
Discussion 
Although gastrin had been hypothesized to have a proliferative autocrine role in 
colorectal neoplasia, gastrin has not been previously detected in neoplastic tissue. Our studies 
are the first to quantitate gastrin and its precursors in human colonic neoplastic and non- 
neoplastic colonic mucosa. 
The presence of gastrin messenger RNA has been reported in colonic neoplastic tissue 
and colon cancer cell lines without reported recovery of the gastrin peptide.(22,23) The 
antibodies utilized in our assay allow for the accurate and specific identification and separation 
of the amidated forms of gastrin and the glycine-extended precursors. The difficulties in 
detecting the peptide in other studies are attributable to assay sensitivity and specificity; antibody 
1611 is specific for amidated gastrin, though specific antibodies for glycine-extended gastrin are 
not available, allowing for the possibility of cross-reactivity with precursor forms of CCK when 
antibody 8237 is utilized. Additionally, in a colonic tissue specimen, increased quantities of 
gastrin precursors were found in relation to processed peptide, possibly indicating altered peptide 
processing in the colon.(24) Prior studies did not include methods to detect precursor forms of 
gastrin, which we have shown to be the predominant forms found in human colonic tissue. 
A comparison of the gastrin and gastrin precursor content between colonic and antral 
tissues revealed important differences. Antral tissues contained larger amounts of amidated 
gastrin, in the range of 860 pmol/g tissue, while the normal-appearing colonic tissue contained 
lesser amounts of gastrin.(25) In contrast to the G-gly/gastrin ratio in these colonic tissues, 
normal antral mucosa and cultured endocrine cells contained significantly larger amounts of 
amidated forms of gastrin when compared to the glycine-extended precursors.(25) Colonic 
tissues contain gastrin precursors in a greatly increased amount, indicating that the colon 
processes gastrin through an altered mechanism. The G-cell is the source of gastrin in the human 
antrum, though the cellular source of the gastrin peptides in the human colon is unknown. 
Differences also exist between neoplastic and non-neoplastic colonic tissues. Gastrin 
content as measured by RIA is slightly, but significantly, decreased in neoplastic tissues 
compared to paired non-neoplastic tissues. Glycine-extended forms of gastrin are significantly 
higher in cancer compared with the normal-appearing adjacent colon, and the neoplastic tissues 
have an increased G-gly/gastrin ratio. Cancer-related changes in the expression or activities of 
the peptide processing enzymes are likely to account for these differences. Tumor heterogeneity 
exists in the colonic tissues that we examined, in a manner analogous to gastrinomas examined 
by our group.(25) This biological variation may help explain the wide range of serum levels of 
gastrin found in patients with colorectal neoplasia. 
The sequence of the gastrin gene, as found in several tumor cell lines, does not differ 
from the normal human gas&in gene sequence.(23,24) It is possible that regulation of 
transcription or differential post-translational processing enzyme activity may account for 
variations in the expression of amidated gastrin. Although these mechanisms were not directly 
addressed in this study, they may also explain the differences in quantities of gastrin and its 
precursors present in the colon when compared with the antrum, as regional variability in the 
activity of enzymes involved in the processing of peptides may occur. Additionally, the 
difference in the tissue ratios of gastrin/gastrin precursors in colorectal neoplasms is most likely 
representative of altered post-translational modification of gastrin. The elevated level of gastrin 
precursors found in the presence of the amidated peptide suggests that multiple enzymes, 
including the carboxypeptidase and amidating enzymes, as illustrated in Figure 1, are not fully 
functional, that quantities of the enzymes are limited, or that precursors are abnormally trafficked 
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within the cells and bypass the processing enzymes. In preliminary studies we have used fast 
protein liquid chromatography to attempt to characterize the molecular forms of gastrin present 
and have found forms that co-elute with known forms of gastrin and G-gly. 
In nude mice with tumor explants from human colon cancer cell lines and in murine 
colon cancer cell lines, gastrin receptors have been demonstrated and gastrin antagonists have 
been shown to inhibit the proliferative response to gastrin and confer a survival advantage for the 
mice.(25,26) In an analogous manner, we speculate that gas&in and/or its processing 
intermediates may be involved in the proliferation of some colonic neoplasms via an autocrine 
mechanism. Pharmacological manipulation of these tumors via receptor antagonists or peptide 
binding antibodies may lead to advances in therapy for colorectal neoplasia. Further studies are 
underway to elucidate the mechanism by which gastrin and/or its precursors are involved in 
colorectal neoplastic proliferation. Additional studies are needed to determine if a 
carboxyamidation enzyme defect is present and to localize the site of peptide production and 
receptors at a cellular level within the colon. 
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